Novel Insights into Schizophrenia Treatment: Comprehensive Analysis Unveiling FGFR1 as a Promising Druggable Gene.

Schizophrenia (SCZ) is a chronic, relapsing mental disorder with a complex and poorly understood etiology. Identifying novel therapeutic targets is essential for advancing treatment options. Druggable genes were sourced from the eQTLGen consortium and integrated with SCZ-related GWAS data. Two-sample Mendelian randomization (MR) and co-localization analyses assessed the likelihood of shared pathogenic variants between the expression quantitative trait loci (eQTL) of these genes and SCZ. Positive results were further validated using Summary-based MR (SMR). Phenome-wide association studies, drug prediction, and molecular docking analyses were also conducted to identify potential therapeutic targets among these genes. SMR analysis revealed six druggable genes significantly associated with SCZ: NMB, IK, FGFR1, SERPING1, EDEM2, and CTSS. Molecular docking studies demonstrated favorable binding energies for PD 173074-FGFR1 (- 8.1407 kcal/mol), WZ-7043-FGFR1 (- 7.8027 kcal/mol), and lenvatinib-FGFR1 (- 7.3075 kcal/mol). Single-cell expression analysis further indicated that FGFR1 is predominantly expressed in mural cells, suggesting its potential role in SCZ pathogenesis. This study identifies six druggable genes as potential therapeutic targets for SCZ, with FGFR1 emerging as a particularly promising candidate. These findings provide valuable insights for SCZ treatment development and position FGFR1 as a viable target for future therapeutic strategies.